View the latest news and SEC filings
Scroll to
One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces one oral presentation
Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona
LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44 th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m.
LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024 and host an investment community conference call
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
April 3, 2017 |
Registration statement for certain foreign private issuers |
F-1 |
Registration Statements |
|
|
April 3, 2017 |
CORRESP |
CORRESP |
Other |
|
|
March 17, 2017 |
UPLOAD |
UPLOAD |
Other |
|
|
March 3, 2017 |
mendment to a previously filed DRS |
DRS/A |
Registration Statements |
|
|
February 13, 2017 |
A statement of beneficial ownership of common stock by certain persons |
SC 13G |
Other |
|
|
January 30, 2017 |
mendment to a previously filed DRS |
DRS/A |
Registration Statements |
|
|
December 21, 2016 |
UPLOAD |
UPLOAD |
Other |
|
|
November 23, 2016 |
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy |
DRS |
Registration Statements |
|
|
July 20, 2016 |
|
D |
Other |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
